CHF110.10
1.27% yesterday
SIX Swiss Exchange, Dec 23, 05:31 pm CET
ISIN
CH0012005267
Symbol
NOVN

Novartis Stock price

CHF110.10
+7.10 6.89% 1M
+15.02 15.80% 6M
+21.40 24.13% YTD
+22.42 25.57% 1Y
+30.82 38.87% 3Y
+36.57 49.74% 5Y
+39.74 56.48% 10Y
+54.01 96.30% 20Y
SIX Swiss Exchange, Closing price Tue, Dec 23 2025
+1.38 1.27%
ISIN
CH0012005267
Symbol
NOVN
Industry

New AI Insights on Novartis Insights AI Insights on Novartis

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
CHF206.9b
Enterprise Value
CHF224.5b
Net debt
CHF17.6b
Cash
CHF7.6b
Shares outstanding
1.9b
Valuation (TTM | estimate)
P/E
18.9 | 15.3
P/S
4.7 | 4.6
EV/Sales
5.1 | 5.0
EV/FCF
16.7
P/B
5.9
Dividends
DPS
CHF3.50
Yield 1Y | 5Y
3.2% | 3.8%
Growth 1Y | 5Y
6.1% | 4.9%
Payout 1Y | 3Y
75.8% | 77.2%
Increased
25 Years
Financials (TTM | estimate)
Revenue
CHF44.1b | CHF44.5b
EBITDA
CHF14.9b | CHF18.6b
EBIT
CHF14.6b | CHF16.8b
Net Income
CHF11.3b | CHF13.8b
Free Cash Flow
CHF13.4b
Growth (TTM | estimate)
Revenue
12.2% | 9.3%
EBITDA
22.7% | 42.8%
EBIT
21.6% | 30.6%
Net Income
-18.2% | 46.4%
Free Cash Flow
29.7%
Margin (TTM | estimate)
Gross
76.1%
EBITDA
33.8% | 41.7%
EBIT
33.1%
Net
25.7% | 30.9%
Free Cash Flow
30.5%
Financial Health
Equity Ratio
43.1%
Return on Equity
27.1%
ROCE
24.6%
ROIC
22.2%
Debt/Equity
0.7
More
EPS
CHF5.8
FCF per Share
CHF7.0
Short interest
-
Employees
76k
Rev per Employee
CHF540.0k
Show more

Create a Free Account to create an Novartis alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Novartis Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Novartis forecast:

14x Buy
45%
13x Hold
42%
4x Sell
13%

Analyst Opinions

31 Analysts have issued a Novartis forecast:

Buy
45%
Hold
42%
Sell
13%

Financial data from Novartis

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
44,128 44,128
12% 12%
100%
- Direct Costs 10,548 10,548
7% 7%
24%
33,579 33,579
14% 14%
76%
- Selling and Administrative Expenses 10,478 10,478
6% 6%
24%
- Research and Development Expense 7,903 7,903
11% 11%
18%
14,917 14,917
23% 23%
34%
- Depreciation and Amortization 306 306
112% 112%
1%
EBIT (Operating Income) EBIT 14,612 14,612
22% 22%
33%
Net Profit 11,337 11,337
18% 18%
26%

In millions CHF.

Don't miss a Thing! We will send you all news about Novartis directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novartis Stock News

AD HOC NEWS
30 days ago
Der Pharmakonzern Novartis CH0012005267 plant einen einschneidenden Stellenabbau an seinem Standort Stein AG.
AD HOC NEWS
about one month ago
Der Pharmakonzern Novartis CH0012005267 will in den kommenden Jahren von seiner Pipeline mit vielversprechenden Medikamentenkandidaten profitieren.
AD HOC NEWS
about one month ago
(Kurs aktualisiert)BASEL - Der Pharmakonzern Novartis CH0012005267 will auch in den kommenden Jahren von seiner Pipeline mit vielversprechenden Medikamentenkandidaten profitieren.
More Novartis News

Company Profile

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Vasant Narasimhan
Employees 75,883
Founded 1996
Website www.novartis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today